OR WAIT null SECS
© 2021 MJH Life Sciences and BioPharm International. All rights reserved.
© 2021 MJH Life Sciences™ and BioPharm International. All rights reserved.
July 21, 2021
Cellares has entered into a strategic relationship with Poseida Therapeutics to advance a closed, automated, and scalable cell therapy manufacturing system.
July 09, 2021
Sparx Therapeutics will build its first commercial manufacturing facility in Yangzhou, China, for antibody drug production.
June 08, 2021
VIVEbiotech has opened its new lentiviral vector manufacturing facilities in Spain, expanding capacity for lentiviral vectors for use in cell and gene therapies.
February 01, 2021
A unified scale-up approach, as presented here, can be applied to any unit operation.
January 04, 2021
Using rDNA technology to synthesize production of proteins and peptide hormones, the biotech startup has achieved synthetic production of insulin, potentially lowering insulin cost by 30%.
December 01, 2020
Scaling needs for potential COVID-19 vaccines depend not only on capacity, but also on supply chain challenges and technological hurdles.
November 24, 2020
Wacker will support production of CureVac’s COVID-19 mRNA-based vaccine candidate at its biotech site in Amsterdam, with production scheduled to start in the first half of 2021.
November 03, 2020
The agreement will provide capacity for the manufacturing of AZD7442, currently being developed for the potential prevention and treatment of COVID-19, at Lonza's Portsmouth, NH site.
October 20, 2020
The company’s new closed cell therapy processing system enables scalable, cost-effective development and manufacturing of cell therapies.
April 01, 2020
Experience, communication, collaboration, transparency, planning, and prioritization contribute to success.